Physician profile
Charles E Thomas
NPI 1205916590
$1,934.67
in general payments reported to CMS, 2019-2025
19 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $57.79 · 2021: $409 · 2022: $121 · 2023: $81.02 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $355.19 | 2019-2025 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $298.22 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals Lp | $188.50 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $158.67 | 2019-2023 | |
| Calliditas Therapeutics US INC. | $144.15 | 2023-2025 | Tarpeyo |
| Amgen INC. | $129.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.70 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $96.92 | 2019-2022 | |
| Vifor Pharma, INC. | $81.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.62 | 2021-2025 | |
| Travere Therapeutics, INC. | $61.78 | 2025 | |
| Aurinia Pharma U.S., INC. | $59.12 | 2021 | |
| Alexion Pharmaceuticals, INC. | $42.77 | 2022-2023 | Ultomiris |
| Ardelyx, INC. | $25.75 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $20.91 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.89 | 2020 | |
| Daiichi Sankyo INC. | $20.42 | 2021 | |
| Abbvie INC. | $20.28 | 2023 | Vraylar |
| Idorsia Pharmaceuticals US INC | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.